Longest survival follow-up ever reported for immunotherapy treatment in this setting
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Hepatitis B infects over 40 million people in India
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Subscribe To Our Newsletter & Stay Updated
